##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549




---

FORM 10-QSB

|  |  |                                                 
|- |  | ------------------------------------------------
|x |  | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
|  |  | OF THE SECURITIES EXCHANGE ACT OF 1934.         

For the Quarterly Period Ended April 30, 2003

|  |  |                                                  
|- |  | -------------------------------------------------
|o |  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
|  |  | OF THE SECURITIES EXCHANGE ACT OF 1934.          

For the Transition Period From         to

Commission file number 0-9922



---

EQUIDYNE CORPORATION

(Name of Small Business Issuer
in Its Charter)


|                                                                        |  |                                                
|----------------------------------------------------------------------- |  | -----------------------------------------------
|Delaware
(State or Other Jurisdiction of
Incorporation or Organization) |  | 04-2608713
(I.R.S. Employer Identification No.)
|                                                                        |  |                                                
|11300 Sorrento Valley Road, Suite 255                                   |  |                                                
|San Diego, California
(Address of principal executive offices)          |  | 92121
(Zip Code)                               

Issuers telephone number, including area code: (858) 587-7777

Check whether the issuer: (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act during the past 12 months
(or for such shorter period that the Registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days. [X]  YES  [  ]  NO

The number of shares outstanding of the Companys common stock as at May 31,
2003 was 14,984,803.

Transitional Small Business Disclosure
Format (check one): [  ]  YES  [X]  NO





---

TABLE OF CONTENTS



|                                      |                                                                   |  |  |  |  |  |  | 
|------------------------------------- | ----------------------------------------------------------------- |  |  |  |  |  |  | 
|PART I    FINANCIAL INFORMATION     
|                                      | Item 1. CONSOLIDATED FINANCIAL STATEMENTS                        
|                                      | Item 2. MANAGEMENTS DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
|                                      | Item 3. CONTROLS AND PROCEDURES                                  
|PART II  OTHER INFORMATION          
|                                      | Item 1. LEGAL PROCEEDINGS                                        
|                                      | Item 2. CHANGES IN SECURITIES AND USE OF PROCEEDS                
|                                      | Item 3. DEFAULTS UPON SENIOR SECURITIES                          
|                                      | Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDER       
|                                      | Item 5. OTHER INFORMATION                                        
|                                      | Item 6. EXHIBITS AND REPORTS ON FORMS 8-K                        
|SIGNATURES                           
|CHIEF EXECUTIVE OFFICER CERTIFICATION
|INDEX TO EXHIBITS                    
|EXHIBIT 99.1                         
|EXHIBIT 99.2                         



---



##### Table of Contents



EQUIDYNE CORPORATION AND SUBSIDIARIES
QUARTERLY REPORT - FORM 10-QSB
THREE AND NINE MONTHS ENDED APRIL 30, 2003

TABLE OF CONTENTS

|        |  |                                                           |  |                |    |      |    | 
|------- |  | --------------------------------------------------------- |  | -------------- | -- | ---- | -- | 
|        |  |                                                           |  |                |    | Page
|        |  |                                                           |  |                |    |     
|PART I 
|Item 1. |  | Consolidated Financial Statements                         |  |                | 2  |     
|Item 2. |  | Managements Discussion and Analysis or Plan of Operation |  |                | 9  |     
|Item 3. |  | Controls and Procedures                                   |  |                | 13 |     
|PART II
|Item 1. |  | Legal Proceedings                                         |  |                | 13 |     
|Item 2. |  | Changes in Securities and Use of Proceeds                 |  |                | 13 |     
|Item 3. |  | Defaults Upon Senior Securities                           |  |                | 13 |     
|Item 4. |  | Submission of Matters to a Vote of Security Holders       |  |                | 13 |     
|Item 5. |  | Other Information                                         |  |                | 14 |     
|Item 6. |  | Exhibits and Reports on Form 8-K                          |  |                | 14 |     
|        |  |                                                           |  | Signatures     |    |      | 14 | 
|        |  |                                                           |  | Certifications |    |      | 15 | 
|        |  |                                                           |  | Exhibits       |    |      | 17 | 

Forward Looking Statements

Certain statements contained in this Quarterly Report and other written
material and oral statements made from time to time by us do not relate
strictly to historical or current facts. As such, they are considered
forward-looking statements that provide current expectations or forecasts of
future events. Such statements are typically characterized by terminology such
as believe, anticipate, should, intend, plan, will, expect,
estimate, project, strategy and similar expressions. Our forward-looking
statements generally relate to the prospects for future sales of our products,
the success of our international marketing activities, the success of our
strategic corporate relationships, the adoption and use of needle-free
technology and the success of our diversification activities. These statements
are based upon assumptions and assessments made by our management in light of
its experience and its perception of historical trends, current conditions,
expected future developments and other factors our management believes to be
appropriate. These forward-looking statements are subject to a number of risks
and uncertainties, including the following: our ability to achieve profitable
operations and to maintain sufficient cash to operate our business and meet our
liquidity requirements: our ability to obtain financing, if required, on terms
acceptable to us, if at all; the success of our research and development
activities and our ability to obtain regulatory authorizations for developed
products, if any; competitive developments affecting our current products; our
ability to successfully attract strategic partners and to market both new and
existing products domestically and internationally; difficulties or delays in
manufacturing; trends toward managed care and health care cost containment;
exposure to product liability and other types of lawsuits and regulatory
proceedings; our ability to protect our intellectual property both domestically
and internationally; governmental laws and regulations affecting domestic and
foreign operations; our ability to identify and complete diversification
opportunities; and the impact of acquisitions, divestitures, restructurings,
product withdrawals and other unusual items. Except as required by applicable
law, the Company undertakes no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.

1



---



##### Table of Contents






PART I  -  FINANCIAL INFORMATION




Item 1. CONSOLIDATED FINANCIAL STATEMENTS

EQUIDYNE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(dollars in thousands, except share amounts)

|                                   |                                                                                                                              |                            |                                            |        |             |        |          |        |        |        | 
|---------------------------------- | ---------------------------------------------------------------------------------------------------------------------------- | -------------------------- | ------------------------------------------ | ------ | ----------- | ------ | -------- | ------ | ------ | ------ | 
|                                   |                                                                                                                              |                            |                                            |        | April 30,   |        | July 31,
|                                   |                                                                                                                              |                            |                                            |        | 2003        |        | 2002    
|                                   |                                                                                                                              |                            |                                            |        |             |        |         
|                                   |                                                                                                                              |                            |                                            |        | (Unaudited) |        |          |        |       
|Assets                             |                                                                                                                              |                            |                                            |        |             |        |          |       
|Current Assets:                    |                                                                                                                              |                            |                                            |        |             |        |          |       
|                                   | Cash and cash equivalents                                                                                                    |                            | $                                          | 10,186 |             |        | $        | 13,092 |       
|                                   | Accounts receivable, net                                                                                                     |                            |                                            | 13     |             |        |          | 52     |       
|                                   | Inventories, net                                                                                                             |                            |                                            | 146    |             |        |          | 234    |       
|                                   | Deferred costs                                                                                                               |                            |                                            | 13     |             |        |          | 20     |       
|                                   | Deferred income taxes                                                                                                        |                            |                                            | 2,664  |             |        |          | 1,921  |       
|                                   | Refundable income taxes                                                                                                      |                            |                                            | 3,446  |             |        |          | 3,446  |       
|                                   | Prepaid and other current assets                                                                                             |                            |                                            | 138    |             |        |          | 64     |       
|                                   |                                                                                                                              |                            |                                            |        |             |        |          |       
|                                   |                                                                                                                              | Total current assets       |                                            |        | 16,606      |        |          |        | 18,829 |       
|Property and equipment, net        |                                                                                                                              |                            | 81                                         |        |             |        | 133      |       
|Deposits                           |                                                                                                                              |                            | 5                                          |        |             |        | 46       |       
|Patents, net                       |                                                                                                                              |                            | 1,495                                      |        |             |        | 1,612    |       
|                                   |                                                                                                                              |                            |                                            |        |             |        |          |       
|                                   |                                                                                                                              |                            | Total assets                               |        | $           | 18,187 |          |        | $      | 20,620 | 
|                                   |                                                                                                                              |                            |                                            |        |             |        |          |       
|Liabilities & Stockholders Equity |                                                                                                                              |                            |                                            |        |             |        |          |       
|Current Liabilities:               |                                                                                                                              |                            |                                            |        |             |        |          |       
|                                   | Accounts payable                                                                                                             |                            | $                                          | 287    |             |        | $        | 334    |       
|                                   | Accrued liabilities                                                                                                          |                            |                                            | 1,023  |             |        |          | 1,382  |       
|                                   | Accrued income taxes                                                                                                         |                            |                                            | 2,324  |             |        |          | 2,612  |       
|                                   | Deferred revenue                                                                                                             |                            |                                            | 25     |             |        |          | 26     |       
|                                   |                                                                                                                              |                            |                                            |        |             |        |          |       
|                                   |                                                                                                                              | Total current liabilities  |                                            |        | 3,659       |        |          |        | 4,354  |       
|Commitments and contingencies      |                                                                                                                              |                            |                                            |        |             |        |          |       
|Stockholders Equity:              |                                                                                                                              |                            |                                            |        |             |        |          |       
|                                   | Common stock, $.10 par value; authorized  35,000,000 shares;
issued  16,481,903 shares at April 30, 2003 and July 31, 2002 |                            |                                            | 1,648  |             |        |          | 1,648  |       
|                                   | Additional paid-in capital                                                                                                   |                            |                                            | 26,593 |             |        |          | 26,593 |       
|                                   | Accumulated deficit                                                                                                          |                            |                                            | (8,400 | )           |        |          | (6,662 | )     
|                                   |                                                                                                                              |                            |                                            |        |             |        |          |       
|                                   |                                                                                                                              |                            | 19,841                                     |        |             |        | 21,579   |       
|                                   | Treasury stock, at cost (1,497,100 shares)                                                                                   |                            |                                            | (5,313 | )           |        |          | (5,313 | )     
|                                   |                                                                                                                              |                            |                                            |        |             |        |          |       
|                                   |                                                                                                                              | Total stockholders equity |                                            |        | 14,528      |        |          |        | 16,266 |       
|                                   |                                                                                                                              |                            |                                            |        |             |        |          |       
|                                   |                                                                                                                              |                            | Total liabilities and stockholders equity |        | $           | 18,187 |          |        | $      | 20,620 | 
|                                   |                                                                                                                              |                            |                                            |        |             |        |          |       

See accompanying notes.

2



---



##### Table of Contents



EQUIDYNE CORPORATION AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)

|                                               |                          |   |                    |     |                   |   |        |       |      |   |        |       |   |   |         |        | 
|---------------------------------------------- | ------------------------ | - | ------------------ | --- | ----------------- | - | ------ | ----- | ---- | - | ------ | ----- | - | - | ------- | ------ | 
|                                               |                          |   | Three Months Ended |     | Nine Months Ended
|                                               |                          |   | April 30,          |     | April 30,        
|                                               |                          |   |                    |     |                  
|                                               |                          |   | 2003               |     | 2002              |   | 2003   |       | 2002
|                                               |                          |   |                    |     |                   |   |        |       |     
|Licensing revenues                             |                          | $ |                  |     |                   | $ | 254    |       |      | $ |      |       |   | $ | 254     |       
|Net product sales                              |                          |   | 14                 |     |                   |   | 35     |       |      |   | 65     |       |   |   | 440     |       
|                                               |                          |   |                    |     |                   |   |        |       |      |   |        |       |   |   |         |       
|                                               |                          |   | 14                 |     |                   |   | 289    |       |      |   | 65     |       |   |   | 694     |       
|Cost of goods sold                             |                          |   | 19                 |     |                   |   | 94     |       |      |   | 70     |       |   |   | 660     |       
|                                               |                          |   |                    |     |                   |   |        |       |      |   |        |       |   |   |         |       
|                                               | Gross profit (loss)      |   |                    | (5  | )                 |   |        | 195   |      |   |        | (5    | ) |   |         | 34     | 
|                                              
|
|Selling, general and administrative expenses   |                          |   | 641                |     |                   |   | 1,135  |       |      |   | 2,367  |       |   |   | 6,385   |       
|Research and development                       |                          |   | 41                 |     |                   |   | 102    |       |      |   | 212    |       |   |   | 397     |       
|Inventory write-down                           |                          |   |                   |     |                   |   |       |       |      |   |      |       |   |   | 295     |       
|Asset impairment and other restructure charges |                          |   |                  |     |                   |   |       |       |      |   |      |       |   |   | 5,511   |       
|                                               |                          |   |                    |     |                   |   |        |       |      |   |        |       |   |   |         |       
|                                               | Total operating expenses |   |                    | 682 |                   |   |        | 1,237 |      |   |        | 2,579 |   |   |         | 12,588 | 
|                                               |                          |   |                    |     |                   |   |        |       |      |   |        |       |   |   |         |       
|Operating loss                                 |                          |   | (687               | )   |                   |   | (1,042 | )     |      |   | (2,584 | )     |   |   | (12,554 | )     
|Interest and other income, net                 |                          |   | 31                 |     |                   |   | 34     |       |      |   | 108    |       |   |   | 379     |       
|                                               |                          |   |                    |     |                   |   |        |       |      |   |        |       |   |   |         |       
|Loss before income tax benefit                 |                          |   | (656               | )   |                   |   | (1,008 | )     |      |   | (2,476 | )     |   |   | (12,175 | )     
|Income tax benefit                             |                          |   | (197               | )   |                   |   | (377   | )     |      |   | (738   | )     |   |   | (3,652  | )     
|                                               |                          |   |                    |     |                   |   |        |       |      |   |        |       |   |   |         |       
|Net loss                                       |                          | $ | (459               | )   |                   | $ | (631   | )     |      | $ | (1,738 | )     |   | $ | (8,523  | )     
|                                               |                          |   |                    |     |                   |   |        |       |      |   |        |       |   |   |         |       
|Net loss per common share, basic               |                          | $ | (0.03              | )   |                   | $ | (0.04  | )     |      | $ | (0.12  | )     |   | $ | (0.57   | )     
|                                               |                          |   |                    |     |                   |   |        |       |      |   |        |       |   |   |         |       
|Net loss per common share, diluted             |                          | $ | (0.03              | )   |                   | $ | (0.04  | )     |      | $ | (0.12  | )     |   | $ | (0.57   | )     
|                                               |                          |   |                    |     |                   |   |        |       |      |   |        |       |   |   |         |       

See accompanying notes.

3



---



##### Table of Contents



EQUIDYNE CORPORATION AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

|                                                                            |                                                |                                                |                                                     |      |                   |        |        |        |        |        |  
|--------------------------------------------------------------------------- | ---------------------------------------------- | ---------------------------------------------- | --------------------------------------------------- | ---- | ----------------- | ------ | ------ | ------ | ------ | ------ | -
|                                                                            |                                                |                                                |                                                     |      | Nine Months Ended
|                                                                            |                                                |                                                |                                                     |      | April 30,        
|                                                                            |                                                |                                                |                                                     |      |                  
|                                                                            |                                                |                                                |                                                     |      | 2003              |        | 2002  
|                                                                            |                                                |                                                |                                                     |      |                   |        |       
|Operating activities:                                                       |                                                |                                                |                                                     |      |                   |        |        |       
|Net loss                                                                    |                                                | $                                              | (1,738                                              | )    |                   | $      | (8,523 | )     
|Adjustments to reconcile net loss to net cash
used in operating activities: |                                                |                                                |                                                     |      |                   |        |        |       
|                                                                            | Depreciation and amortization                  |                                                |                                                     | 194  |                   |        |        | 422    |       
|                                                                            | Deferred income taxes                          |                                                |                                                     | (743 | )                 |        |        | (3,653 | )     
|                                                                            | Loss on sale of property and equipment         |                                                |                                                     | 9    |                   |        |        |       |       
|                                                                            | Asset impairment and other restructure charges |                                                |                                                     |    |                   |        |        | 5,278  |       
|                                                                            | Changes in operating assets and liabilities:   |                                                |                                                     |      |                   |        |        |        |       
|                                                                            |                                                | Accounts receivable                            |                                                     |      | 39                |        |        |        | 37     |       
|                                                                            |                                                | Inventories                                    |                                                     |      | 88                |        |        |        | (45    | )     
|                                                                            |                                                | Other assets                                   |                                                     |      | (46               | )      |        |        | 215    |       
|                                                                            |                                                | Accounts payable and other current liabilities |                                                     |      | (695              | )      |        |        | (1,272 | )     
|                                                                            |                                                |                                                |                                                     |      |                   |        |        |       
|                                                                            |                                                |                                                | Net cash used in operating activities               |      |                   | (2,892 | )      |        |        | (7,541 | )
|Investing activities:                                                       |                                                |                                                |                                                     |      |                   |        |        |       
|Proceeds from held to maturity securities                                   |                                                |                                                |                                                   |      |                   |        | 7,207  |       
|Proceeds from sale of property and equipment                                |                                                |                                                | 7                                                   |      |                   |        |       |       
|Purchase of property and equipment and deposits on tooling
and equipment    |                                                |                                                | (21                                                 | )    |                   |        | (1,559 | )     
|                                                                            |                                                |                                                |                                                     |      |                   |        |        |       
|                                                                            |                                                |                                                | Net cash provided by (used in) investing activities |      |                   | (14    | )      |        |        | 5,648  |  
|Financing activities:                                                       |                                                |                                                |                                                    |      |                   |        |       |       
|                                                                            |                                                |                                                |                                                     |      |                   |        |        |       
|Decrease in cash and cash equivalents                                       |                                                |                                                | (2,906                                              | )    |                   |        | (1,893 | )     
|Cash and cash equivalents, beginning of period                              |                                                |                                                | 13,092                                              |      |                   |        | 15,405 |       
|                                                                            |                                                |                                                |                                                     |      |                   |        |        |       
|Cash and cash equivalents, end of period                                    |                                                | $                                              | 10,186                                              |      |                   | $      | 13,512 |       
|                                                                            |                                                |                                                |                                                     |      |                   |        |        |       
|Supplemental cash flow information:                                         |                                                |                                                |                                                     |      |                   |        |        |       
|Income taxes paid                                                           |                                                | $                                              | 293                                                 |      |                   | $      | 301    |       
|Non-cash transactions - exercise of stock options                           |                                                |                                                |                                                   |      |                   |        | 3      |       

See accompanying notes.

4



---



##### Table of Contents



EQUIDYNE CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1.   Description of Business and Summary of Significant Accounting Policies

Description of Business

Equidyne Corporation (the Company) is a holding company, which since its
formation in 1977, has invested in various medical device companies and
technologies. The Company presently has three wholly-owned subsidiaries:
Equidyne Systems, Inc. (ESI), a California corporation acquired in May 1998,
Equidyne Holdings (Holdings), a Massachusetts Business Trust formed in August
2000, and Dynamic Dental Systems, Inc. (DDS), a Georgia corporation acquired
in May 1998, which is currently inactive. ESI, since its formation in August
1993, has been engaged in developing, manufacturing and selling its patented,
needle-free drug delivery systems, principally the reusable INJEX System.
Since January 1999, the Company has focused on the development of ESIs
needle-free technologies. Other lines of business at that time were
discontinued or divested.

During fiscal 2002, the Companys new executive management began an
evaluation of the Companys technologies, markets and production capabilities.
They concluded that a change in the strategic focus of the Company was
necessary as the Companys production capabilities were not cost effective nor
were its sales and marketing programs generating satisfactory results. The
Company believed that more stockholder value could be created through licensing
agreements and/or strategic partnerships with pharmaceutical, biotech, medical
device or other interested companies. The Company believed its strategic
objectives would be further enhanced by targeted development of disposable
needle-free injection systems. In addition, the Company began evaluating
various diversification strategies, including, but not limited to, investing in
business opportunities not necessarily related to the medical device field.
This evaluation is on-going.

Basis of Presentation

The accompanying unaudited interim consolidated financial statements
contain all adjustments (consisting of normal recurring adjustments) which are,
in the opinion of management, necessary for a fair and accurate presentation of
the Companys financial position at April 30, 2003 and the results of its
operations for the three and nine-month periods ended April 30, 2003 and April
30, 2002. These interim financial statements should be read in conjunction with
the Companys audited consolidated financial statements and notes thereto
included in its Annual Report on Form 10-KSB for the year ended July 31, 2002.
Interim results are not necessarily indicative of those to be expected for the
full year.

The accompanying consolidated financial statements include the accounts of
the Company and its subsidiaries. All material intercompany transactions have
been eliminated.

Revenue Recognition

The Company recognizes revenue in accordance with Staff Accounting
Bulletin No. 101, Revenue Recognition in Financial Statements.The Companys
products are sold subject to rights of return of generally between 90 days and
180 days, as defined by the sales agreement. In addition, the Companys INJEX
System has a limited shelf life, and certain retailers and wholesalers can
return these products to the Company up to six months beyond this expiration
date. As a result of these rights of return and the current availability of
historical trends in sales and product returns, the Company defers recognition
of revenues and the related cost of inventory shipped until the expiration of
all such rights of return. As of April 30, 2003 and July 31, 2002, deferred
revenue was approximately $25,000 and $26,000, respectively. The related cost
of the inventory shipped of approximately $13,000 and $20,000 at April 30, 2003
and July 31, 2002, respectively has also been deferred, to be recognized
concurrent with the recognition of the related revenue.

5



---



##### Table of Contents



Use of Estimates

The preparation of financial statements in conformity with generally
accepted accounting principles requires the Companys management to make
estimates and assumptions that affect the amounts reported in the financial
statements and accompanying notes. Actual results could differ from those
estimates.

Recent Accounting Pronouncements

In July 2002, the Financial Accounting Standards Board (FASB) issued
Statement No. 146, Accounting for Costs Associated with Exit or Disposal
Activities(FAS 146). The standard requires companies to recognize costs
associated with exit or disposal activities when they are incurred rather than
at the date of a commitment to an exit or disposal plan. Examples of costs
covered by the standard include lease termination costs and certain employee
severance costs that are associated with a restructuring, discontinued
operation, plant closing, or other exit or disposal activity. Previous
accounting guidance was provided by Emerging Issue Task Force (EITF) Issue
No. 94-3, Liability Recognition for Certain Employee Termination Benefits and
Other Costs to Exit an Activity (including Certain Costs Incurred in a
Restructuring).FAS 146 replaces Issue No. 94-3. FAS 146 is to be applied
prospectively to exit or disposal activities initiated after December 31, 2002.
FAS 146 is not expected to have any material effect on the Companys financial
statements.

Reclassifications

Certain reclassifications have been made to prior year amounts to conform
to current year classifications.

2.   Inventories

Inventories consist of the following (in thousands):

|               |  |           |     |          |  |   |     | 
|-------------- |  | --------- | --- | -------- |  | - | --- | 
|               |  | April 30, |     | July 31,
|               |  | 2003      |     | 2002    
|               |  |           |     |         
|Raw materials  |  | $         | 48  |          |  | $ | 96  | 
|Finished goods |  |           | 98  |          |  |   | 138 | 
|               |  |           |     |          |  |   |     | 
|               |  | $         | 146 |          |  | $ | 234 | 
|               |  |           |     |          |  |   |     | 

3.   Loss per Share

Basic loss per share is based upon the weighted average number of common
shares outstanding during the period. Diluted loss per share reflects the
effect of dilutive securities, if any, principally stock options and warrants.
Dilutive securities were not included in the calculation of diluted weighted
average shares for the three and nine months ended April 30, 2003 and 2002, due
to their anti-dilutive effect. The following table sets forth the computation
of basic and diluted loss per share (in thousands, except per share amounts):

|                                       |  |                    |        |                   |  |      |        |      |  |   |        |   |  |   |        |  
|-------------------------------------- |  | ------------------ | ------ | ----------------- |  | ---- | ------ | ---- |  | - | ------ | - |  | - | ------ | -
|                                       |  | Three Months Ended |        | Nine Months Ended
|                                       |  | April 30,          |        | April 30,        
|                                       |  |                    |        |                  
|                                       |  | 2003               |        | 2002              |  | 2003 |        | 2002
|                                       |  |                    |        |                   |  |      |        |     
|Net loss                               |  | $                  | (459   | )                 |  | $    | (631   | )    |  | $ | (1,738 | ) |  | $ | (8,523 | )
|                                       |  |                    |        |                   |  |      |        |      |  |   |        |   |  |   |        |  
|Weighted-average shares                |  |                    | 14,985 |                   |  |      | 14,985 |      |  |   | 14,985 |   |  |   | 14,985 |  
|                                       |  |                    |        |                   |  |      |        |      |  |   |        |   |  |   |        |  
|Net loss per share (Basic and Diluted) |  | $                  | (0.03  | )                 |  | $    | (0.04  | )    |  | $ | (0.12  | ) |  | $ | (0.57  | )
|                                       |  |                    |        |                   |  |      |        |      |  |   |        |   |  |   |        |  

6



---



##### Table of Contents



4.   Stock-Based Compensation

In accordance with Statement No. 123, Accounting for Stock-Based
Compensation(FAS 123), the Company accounts for its two stock option plans
and other stock-based employee compensation using the intrinsic value method
prescribed by Accounting Principles Board (APB) Opinion No. 25, Accounting
for Stock Issued to Employees,and related interpretations. Accordingly,
compensation expense is recorded on the date of grant only to the extent the
current market price of the underlying stock exceeds the option exercise price.
The Company did not record any stock-based compensation expense in the three
and nine months ended April 30, 2003 and 2002.

In December 2002, the FASB issued Statement No. 148, Accounting for
Stock-Based Compensation  Transition and Disclosure(FAS 148), an amendment
of FAS 123. FAS 148 provides alternative methods of transition for a voluntary
change to the fair value based method of accounting for stock-based
compensation. In addition, FAS 148 amends the disclosure requirements of FAS
123 to require more prominent and frequent disclosures in financial statements
about the method of accounting for stock-based compensation and the effect of
the method used on reported results. The Company will continue to apply
Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to
Employees.Accordingly, the adoption of this standard had no material impact
on its financial position, results of operations or cash flows. The interim
disclosure provisions of FAS 148 are effective for interim reporting periods
beginning after December 15, 2002. As such, the Company adopted the disclosure
provisions beginning with the third quarter of fiscal 2003.

Had compensation expense been determined based on the fair values at dates
of grant for its stock options under FAS 123, as amended by FAS 148, net loss
and net loss per share would have been reported as indicated in the pro forma
results below (in thousands, except per share amounts):

|                                                                                           |  |                    |       |                   |  |      |       |      |  |   |        |   |  |   |        |  
|------------------------------------------------------------------------------------------ |  | ------------------ | ----- | ----------------- |  | ---- | ----- | ---- |  | - | ------ | - |  | - | ------ | -
|                                                                                           |  | Three Months Ended |       | Nine Months Ended
|                                                                                           |  | April 30,          |       | April 30,        
|                                                                                           |  |                    |       |                  
|                                                                                           |  | 2003               |       | 2002              |  | 2003 |       | 2002
|                                                                                           |  |                    |       |                   |  |      |       |     
|Net loss, as reported                                                                      |  | $                  | (459  | )                 |  | $    | (631  | )    |  | $ | (1,738 | ) |  | $ | (8,523 | )
|Add: Stock-based compensation
expense included in reported
net loss                        |  |                    |     |                   |  |      |     |      |  |   |      |   |  |   |      |  
|Deduct: Stock-based employee
compensation expense
determined under fair value
based method |  |                    | (95   | )                 |  |      | (65   | )    |  |   | (286   | ) |  |   | (194   | )
|                                                                                           |  |                    |       |                   |  |      |       |      |  |   |        |   |  |   |        |  
|Pro forma net loss                                                                         |  | $                  | (554  | )                 |  | $    | (696  | )    |  | $ | (2,024 | ) |  | $ | (8,717 | )
|                                                                                           |  |                    |       |                   |  |      |       |      |  |   |        |   |  |   |        |  
|Net loss per share, as reported                                                            |  | $                  | (0.03 | )                 |  | $    | (0.04 | )    |  | $ | (0.12  | ) |  | $ | (0.57  | )
|                                                                                           |  |                    |       |                   |  |      |       |      |  |   |        |   |  |   |        |  
|Net loss per share, pro forma                                                              |  | $                  | (0.04 | )                 |  | $    | (0.05 | )    |  | $ | (0.14  | ) |  | $ | (0.58  | )
|                                                                                           |  |                    |       |                   |  |      |       |      |  |   |        |   |  |   |        |  

The fair values under FAS 123 for options granted were estimated at the
date of grant using a Black-Scholes option pricing model with the following
weighted-average assumptions:

|                      |  |      |      |      |  |  |      |  
|--------------------- |  | ---- | ---- | ---- |  |  | ---- | -
|                      |  | 2003 |      | 2002
|                      |  |      |      |     
|Expected life (years) |  |      | 3    |      |  |  | 3    |  
|Interest rate         |  |      | 4.0  | %    |  |  | 5.0  | %
|Volatility            |  |      | 0.95 |      |  |  | 0.94 |  
|Dividend yield        |  |      | 0.0  | %    |  |  | 0.0  | %

7



---



##### Table of Contents



5.   Contingencies

In the ordinary course of conducting its business, the Company may become
subject to litigation and claims regarding various matters. There exists a
reasonable possibility that the Company will not prevail in all cases.
Although sufficient uncertainty exists in these cases to prevent the Company
from determining the amount of its liability, if any, the ultimate exposure
upon the resolution of any such litigation or claims is not expected to
materially adversely affect the Companys financial condition or results of
operations.

6.   Prior Year Asset Impairment and Other Restructure Charges

In the nine months ended April 30, 2002, the Company recorded $5.5 million
in pre-tax charges ($5.4 million of such charges were recorded in the second
quarter of fiscal 2002) related to asset impairment losses. The
charges principally related to a $5.3 million charge due to the impairment of
value of certain non-operating assets (primarily its automated manufacturing
equipment and tooling) and approximately $0.2 million for employee severance
and excess facility costs. Additionally, during the second quarter of fiscal
2002, the Company recorded a charge of $295,000, shown as a separate component
of operating expenses in the caption inventory write-down in the accompanying
Statement of Operations, resulting from the settlement of litigation with a
former manufacturer of its injectors and reset boxes.

8



---



##### Table of Contents






Item 2. MANAGEMENTS DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

Overview

Equidyne Corporation (the Company) is a holding company, which since its
formation in 1977, has invested in various medical device companies and
technologies. The Company presently has three wholly-owned subsidiaries:
Equidyne Systems, Inc. (ESI), a California corporation acquired in May 1998,
Equidyne Holdings (Holdings), a Massachusetts Business Trust formed in August
2000, and Dynamic Dental Systems, Inc. (DDS), a Georgia corporation acquired
in May 1998, which is currently inactive. ESI, since its formation in August
1993, has been engaged in developing, manufacturing and selling its patented,
needle-free drug delivery systems, principally the reusable INJEX System.
Since January 1999, other than the needle-free technology of ESI, the Companys
other lines of business at that time were discontinued or divested.

From January 1999 to December 2001, the Companys focus, through ESI, was
centered on the sales, marketing and production of its reusable INJEX 30 and
INJEX 50 Systems. The Company launched its INJEX 30 System to the U.S.
diabetes market in July 2000, utilizing a direct sales force of more than 50
persons. Since the U.S. launch, the Company entered into distribution
agreements with several large distribution partners to expand distribution
channels and obtained Generic Product Indicator (GPI) codes for the purpose
of facilitating reimbursement through health insurance plans and pharmacy
benefit managers. However, none of the Companys sales and marketing efforts
resulted in the volume of sales anticipated by the Companys prior management.

In December 2001, the Companys Board of Directors appointed Marcus R.
Rowan, a director of the Company, as Chief Executive Officer and appointed Mark
C. Myers, a consultant to the Company, as President. Mr. Myers was appointed
to the Board of Directors in January 2002. New management concluded after an
evaluation of the needle-free industry and the status of the Companys
competitors that a change in the strategic focus of the Company was necessary
as the Companys sales and marketing programs were not generating satisfactory
results. The evaluation also determined that the Companys research program
should focus on continuing the development of disposable systems (both
pre-filled and variable dosage devices) that could potentially serve as the
basis for licensing agreements and/or strategic partnerships with
pharmaceutical, biotech, medical device or other interested companies.

While the Company is continuing sales of the INJEX 30 System into the
diabetes market from its existing inventories, the Company has increased its
efforts to develop strategic partnerships and licensing arrangements with
pharmaceutical, biotech, medical device and other interested companies.
Through an agreement with the Companys former wholly-owned subsidiary, Rosch
AG Medizintechnik (Rosch), the Company participated in a licensing
arrangement with Pfizer (formerly Pharmacia AB) (Pfizer) for the worldwide
use of the Injex System for human growth hormone treatment. In January 2003,
Rosch declared bankruptcy under German law, terminating the Pfizer agreement.
In March 2003, the assets of Rosch were purchased by Riemser Arzneimitel AG
(Riemser), a private company located in Germany. Equidyne and Riesmer are in
discussions with Pfizer about re-establishing the licensing agreement, though
there can be no assurances that a new agreement will be entered into.
Nevertheless, the Company believes more stockholder value can be derived from
licensing its intellectual property than from retail sales activities, and the
focus of the Company has shifted from an exclusive focus on its reusable
devices to one which places additional emphasis on more recent technology
developments, licensing opportunities for the Companys existing technology and
evaluating other diversification opportunities for the Company. As part of
this change in focus, the Company has postponed ramping up manufacturing of the
INJEX 50 and disposable systems pending successful development of strategic
partnerships or licensing arrangements designed to facilitate the introduction
of these systems into the market.

As a result of the Boards decision to change the Companys strategic
direction, the Company recorded a pre-tax charge of $5.5 million principally
related to asset impairment losses in the second quarter ended January 31,
2002. Since the second half of fiscal 2002, the Company has been evaluating
various

9



---



##### Table of Contents



diversification strategies, including, but not limited to, investing in
business opportunities not necessarily related to the medical device field.
This evaluation is on-going.

Results of Operations

Consolidated net product sales (sales) were $14,000 for the three months
ended April 30, 2003 compared to $35,000 for the three months ended April 30,
2002, a decrease of $21,000, or 60%. Sales were $65,000 and $440,000 for the
nine months ended April 30, 2003 and 2002, respectively. The decrease in sales
through the Companys distribution partners (Rite-Aid and CVS) reflects the
Companys change in strategic focus described above and the cessation of
advertising and co-marketing expenditures in the third quarter of the prior
fiscal year. Such advertising and marketing expenditures have not proven to be
effective in generating product sales.

In the three months ended April 30, 2002, the Company received $254,000 in
licensing revenues from Rosch related to the contract with Pfizer. Since the
fourth quarter of fiscal 2002, the Company has not received additional
licensing revenues from this contract.

Cost of sales for the three and nine months ended April 30, 2003 was
$19,000 and $70,000, respectively, as compared to $94,000 and $660,000,
respectively in the three and nine month periods in the 2002 fiscal year. This
represents a decrease in cost of sales of 80% and 89% in the three and nine
month periods, respectively. The decrease in the current fiscal year was
primarily the result of the decrease in sales volume. The low gross margin
results from the production cost of the consumable components of the Companys
products (the polycarbonate plastic ampules and vial adapters) which is in
excess of the respective selling prices both in the current and prior fiscal
years, primarily resulting from low production volumes. Cost of sales for
fiscal 2002 was further impacted by a write-down of the Companys ampule and
adapter inventories to reduce their respective carrying values to the lower of
cost or selling price. However, the Company believes the high cost structure
for production will continue until demand for its products enables it to
achieve greater production volumes.

Selling, general and administrative (SG&A) expenses for the three months
ended April 30, 2003 were $641,000, compared to $1,135,000 for the three months
ended April 30, 2002, a decrease of $494,000, or 44%. SG&A expenses in the
nine months ended April 30, 2003 were $2,367,000, a decrease of $4,018,000, or
63% from the $6,385,000 in the first nine months of the prior fiscal year. The
decrease in both the three and nine month periods principally reflects lower
total salary expense, recruiting and travel related costs resulting from the
reductions of the Company sales force and other administrative staff between
October 2001 and March 2002. The Company reduced its sales force by 18 sales
representatives in October 2001 and made reductions in other administrative
staff between January and March 2002. Total headcount was reduced from 47
employees in July 2001 to 7 employees as of April 2003. The current fiscal
year also includes the compensation of Mr. Rowan and Mr. Myers who were
appointed as Chief Executive Officer and President, respectively, in December
2001 and total executive management bonuses of $187,000, an increase of $47,000
from the $140,000 incurred in the nine months ended April 30, 2002.
Advertising and co-marketing expenditures in the nine month period were reduced
by $850,000, as compared to the prior fiscal year, as a result of the
aforementioned cessation of advertising and co-marketing activities.
Consulting, outside services and other professional service expenditures
decreased by approximately $210,000 from the third quarter in the prior fiscal
year. These service expenditures decreased $1,465,000 as compared to the first
nine months of the prior fiscal year as the Company has scaled-back operations
and changed its strategic focus and thus required fewer such services.
Reductions included approximately $200,000 of audit and tax service costs and
approximately $290,000 of consulting costs associated with a voluntary exchange
program completed in the second quarter of fiscal 2002. In addition,
depreciation and amortization expense for the nine months ended April 30, 2003
decreased approximately $227,000 as the result of the $5.3 million write-off of
the Companys manufacturing equipment in the second quarter of fiscal 2002.
The second quarter of the prior fiscal year included a $120,000 bonus paid to
Mr. Rowan for his services to the Board during the first five months of fiscal
2002.

10



---



##### Table of Contents



Research and development expenses decreased 60% to $41,000 for the three
months ended April 30, 2003 from $102,000 for the three months ended April 30,
2002. Nine-month expenditures for research and development decreased 47% to
$212,000 from $397,000 in the prior year. Having completed its targeted
development efforts, the Company discontinued its research and development
activities in February 2003. Additionally, the Company performed fewer
clinical trial tests during the current fiscal year than in the prior fiscal
year. The Company believes its previous developmental efforts in fiscal 2003
have enhanced its needle-free system offerings, particularly its disposable,
single-use models, and a newly-designed glass-lined pre-filled ampule, which
would allow the Company to have product offerings that could serve as the basis
for licensing agreements and/or strategic partnerships with pharmaceutical,
biotech, medical device or other interested companies.

In the nine months ended April 30, 2002, the Company recorded $5.5 million
in pre-tax charges ($5.4 million of such charges were recorded in the second
quarter) related to asset impairment losses. The charges principally related
to a $5.3 million loss due to the impairment of value of certain non-operating
assets (primarily its automated manufacturing equipment and tools) and
approximately $0.2 million for employee severance and excess facility costs.
Also in the second quarter of fiscal 2002, the Company recorded a charge of
$295,000, shown as a separate component of operating expenses in the caption
inventory write-down in the accompanying Statement of Operations, resulting
from the settlement of litigation with a former manufacturer of its injectors
and reset boxes.

The Companys income tax benefit for the three and nine-months ended April
30, 2003 were $197,000 and $738,000, respectively, as compared to $377,000 and
$3,652,000 for the three and nine months ended April 30, 2002. The tax
benefits are based on the Companys ability to carry back the operating losses
incurred to recapture a portion of the taxes paid in fiscal year 2001.

Liquidity and Capital Resources

At April 30, 2003, the Company had working capital of $12.9 million,
compared to working capital of $14.5 million at July 31, 2002. The decrease of
approximately $1.6 million resulted primarily from the net effect of the
Companys operating losses for the first nine months of the current fiscal
year.

The Company believes that funds on hand, combined with cash generated from
investment income and tax refunds, will be sufficient to finance operations and
capital expenditures for the next twelve months. In addition, the Company may
consider enhancing future growth through investments in or acquisitions of
companies, technologies or products in related or other lines of business, as
well as through expansion of the existing product lines. There is no assurance
that management will find suitable opportunities or effect the necessary
financial arrangements for such investments or provide the working capital
needed for the acquired activities.

Critical Accounting Policies

The Consolidated Financial Statements have been prepared in accordance
with accounting principles generally accepted in the United States, which
require the Company to make estimates and assumptions that affect the reported
amounts of assets and liabilities at the date of the Consolidated Financial
Statements, and revenues and expenses during the periods reported. Actual
results could differ from those estimates. The Company believes the following
are the critical accounting policies which could have the most significant
effect on the Companys reported results and require the most difficult,
subjective or complex judgments by management.

Excess and Obsolete Inventory

Inventories are stated at the lower of cost or market, with cost
determined at a weighted average of purchased costs. In evaluating whether
inventory is stated at the lower of cost or market, management considers such
factors as the amount of inventory on hand, expiration dates, and the estimated
time to sell such

11



---



##### Table of Contents



inventory. As appropriate, provisions are made to reduce inventories to
their net realizable value. Historically, cost of inventories that potentially
may not sell prior to expiration or are deemed of no commercial value have been
written-off when identified.

Revenue Recognition

The Company recognizes revenue in accordance with Staff Accounting
Bulletin No. 101, Revenue Recognition in Financial Statements.The Companys
products are sold subject to rights of return of generally between 90 days and
180 days, as defined by the sales agreement. In addition, the Companys INJEX
System has a limited shelf life, and certain retailers and wholesalers can
return these products to the Company up to six months beyond this expiration
date. As a result of these rights of return and the current availability of
historical trends in sales and product returns, the Company defers recognition
of revenues and the related cost of inventory shipped until the expiration of
all such rights of return.

Impairment of Long-Lived Assets

The Company periodically evaluates the carrying value of the unamortized
balances of its long-lived assets (property and equipment and patents) to
determine whether any impairment of these assets has occurred or whether any
revision to the related amortization periods should be made. This evaluation is
based on managements projections of the undiscounted future cash flows
associated with each class of asset. If managements evaluation indicates that
the carrying values of these assets were impaired, such impairment is
recognized by a reduction of the applicable asset carrying value to its
estimated fair value and expensed through operations.

Income Taxes

In preparing the Companys consolidated financial statements, management
is required to estimate the Companys income taxes in each of the jurisdictions
in which it operates. This process involves estimating actual current tax
liabilities together with assessing temporary differences resulting from
differing treatment of items for tax and accounting purposes. These
differences result in deferred tax assets and liabilities which are included
within the consolidated balance sheet, as applicable. The Companys deferred
tax assets consist primarily of net operating losses carried back and the
effects of certain reserves not yet deductible for tax purposes. Management
will then assess the likelihood that deferred tax assets will be recovered from
future taxable income, and, to the extent that it is believed that recovery is
not more likely than not, a valuation allowance is established. Although the
Company believes that Federal deferred tax assets will be realized via future
carry back of operating losses, the Company determined that it does not have
sufficient taxable income available for future carry back with respect to State
income taxes. Therefore, the Company believes it was appropriate to record a
valuation allowance against its State deferred tax assets. The State deferred
tax assets are still available for the Company to use in the future to offset
State taxable income, which would result in the recognition of a tax benefit
and a reduction to the Companys effective tax rate.

New Accounting Pronouncements

In July 2002, the Financial Accounting Standards Board (FASB) has issued
Statement No. 146, Accounting for Costs Associated with Exit or Disposal
Activities(FAS 146). The standard requires companies to recognize costs
associated with exit or disposal activities when they are incurred rather than
at the date of a commitment to an exit or disposal plan. Examples of costs
covered by the standard include lease termination costs and certain employee
severance costs that are associated with a restructuring, discontinued
operation, plant closing, or other exit or disposal activity. Previous
accounting guidance was provided by Emerging Issue Task Force (EITF) Issue
No. 94-3, Liability Recognition for Certain Employee Termination Benefits and
Other Costs to Exit an Activity (including Certain Costs Incurred in a
Restructuring).FAS 146 replaces Issue No. 94-3. FAS 146 is to be applied
prospectively to exit or disposal activities initiated after December 31, 2002.
FAS 146 is not expected to have any material effect on the Companys financial
statements.

12



---



##### Table of Contents



On December 31, 2002, the FASB issued Statement No. 148, Accounting for
Stock-Based Compensation  Transition and Disclosure(FAS 148), which amends
Statement No. 123, Accounting for Stock-Based Compensation(FAS 123). FAS
148 provides alternative methods of transition for a voluntary change to the
fair value based method of accounting for stock-based compensation. In
addition, FAS 148 amends the disclosure requirements of FAS 123 to require more
prominent and more frequent disclosures in financial statements of the effects
of stock-based compensation. The Company will continue to apply Accounting
Principles Board Opinion No. 25, Accounting for Stock Issued to Employees.
Accordingly, the adoption of this standard had no material impact on its
financial position, results of operations or cash flows.




Item 3. CONTROLS AND PROCEDURES

(a)  Evaluation of Disclosure Controls and Procedures.



| |  | The Companys Chief Executive Officer and Chief Financial Officer have
evaluated the effectiveness of the design and operation of the Companys
disclosure controls and procedures (as such term is defined in Rules
13(a) -14(c) and 15(d)-14(c) under the Securities Exchange Act of 1934,
as amended (the Exchange Act)) as of a date within 90 days prior to the
filing date of this quarterly report (the Evaluation Date). Based on
such evaluation, such officers have concluded that, as of the Evaluation
Date, the Companys disclosure controls and procedures are effective to
ensure that such officers are alerted on a timely basis to material
information relating to the Company (including its consolidated
subsidiaries) required to be included in the Companys reports filed or
submitted under the Exchange Act and that such information is recorded,
processed and reported as and when required.
| |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(b)  Changes in Internal Controls.



| |  | Since the Evaluation Date, there have not been any significant changes in
the Companys internal controls or in other factors that could
significantly affect such controls.
| |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------




PART II  OTHER INFORMATION




Item 1. LEGAL PROCEEDINGS

In the ordinary course of conducting its business, the Company has become
subject to litigation and claims regarding various matters. There exists a
reasonable possibility that the Company will not prevail in all cases.
Although sufficient uncertainty exists in these cases to prevent the Company
from determining the amount of its liability, if any, the ultimate exposure
upon the resolution of any such litigation or claims is not expected to
materially adversely affect the Companys financial condition or results of
operations.




Item 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

None.




Item 3. DEFAULTS UPON SENIOR SECURITIES

None.




Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDER

None.

13



---



##### Table of Contents






Item 5. OTHER INFORMATION

In accordance with Section 10A(i)(2) of the Securities Exchange Act of
1934, as added by Section 202 of the Sarbanes-Oxley Act of 2002 (the Act), we
are required to disclose the non-audit services approved by our Audit Committee
to be performed by our independent accountants. Non-audit services are defined
in the Act as services other than those provided in connection with an audit or
a review of the financial statements of a company. No non-audit services were
performed during the third quarter ended April 30, 2003.




Item 6. EXHIBITS AND REPORTS ON FORMS 8-K



| | (a) |  | Exhibits                                                                                                                                                                                                                     
| | --- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| |     |  | See Index to Exhibits included in this quarterly report.                                                                                                                                                                     
|
| | (b) |  | Reports on Form 8-K:                                                                                                                                                                                                         
|
| |     |  | On March 7, 2003 the Company filed a Report on Form 8-K related to
change in its independent public accountants pursuant to a merger of
its independent public accountants and another accounting and business
services firm.




SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.

EQUIDYNE CORPORATION

(Registrant)

|                     |  |     |  |                                             
|-------------------- |  | --- |  | --------------------------------------------
|Dated: June 12, 2003 |  | By: |  | /s/ Marcus R. Rowan                         
|                     |  |     |  |                                             
|                     |  |     |  | Marcus R. Rowan                             
|                     |  |     |  | Chief Executive Officer                     
|                     |  |     |  |                                             
|                     |  |     |  |                                             
|                     |  | By: |  | /s/ Jeffery B. Weinress                     
|                     |  |     |  |                                             
|                     |  |     |  | Jeffery B. Weinress                         
|                     |  |     |  | Chief Financial Officer                     
|                     |  |     |  | (principal financial and accounting officer)

14



---



##### Table of Contents






CHIEF EXECUTIVE OFFICER CERTIFICATION

I, Marcus R. Rowan, Chief Executive Officer of Equidyne Corporation,
certify that:



|1. |  | I have reviewed this quarterly report on Form 10-QSB of Equidyne
Corporation (Equidyne);                                                                                                                                                                                                                                    
|-- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|  
|2. |  | Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by
this quarterly report;
|  
|3. |  | Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all
material respects the financial condition, results of operations and cash
flows of Equidyne as of, and for, the periods presented in this quarterly
report;                         
|  
|4. |  | Equidynes other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures and
internal controls and procedures (as defined in Exchange Act Rules 13a-14
and 15d-14) for Equidyne and have:                                                                                



| | a) |  | designed such disclosure controls and procedures to ensure
that material information relating to Equidyne, including its
consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this
quarterly report is being prepared;
| | -- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| | b) |  | evaluated the effectiveness of Equidynes disclosure controls
and procedures as of a date within 90 days prior to the filing date
of this quarterly report (the Evaluation Date); and                                                                                                  
|
| | c) |  | presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;                                                                                                                  



|5. |  | Equidynes other certifying officer and I have disclosed, based on our
most recent evaluation, to Equidynes auditors and the audit committee of
Equidynes board of directors:
|-- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | a) |  | all significant deficiencies in the design or operation of
internal controls which could adversely affect Equidynes ability to
record, process, summarize and report financial data and have
identified for Equidynes auditors any material weaknesses in
internal controls; and
| | -- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| | b) |  | any fraud, whether or not material, that involves management
or other employees who have a significant role in Equidynes
internal controls; and                                                                                                                                  



|6. |  | Equidynes other certifying officer and I have indicated in this
quarterly report whether or not there were any significant changes in
Equidynes internal controls or in other factors that could significantly
affect internal controls subsequent to the date of our most recent
evaluation, including any corrective actions with regard to significant
deficiencies and material weaknesses.
|-- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Date: June 12, 2003.

| |     |                        
| | --- | -----------------------
| | By: | /s/ Marcus R. Rowan    
| |     |                        
| |     | Marcus R. Rowan        
| |     | Chief Executive Officer

15



---



##### Table of Contents



CHIEF FINANCIAL OFFICER CERTIFICATION

I, Jeffery B. Weinress, Chief Financial Officer of Equidyne Corporation,
certify that:



|1. |  | I have reviewed this quarterly report on Form 10-QSB of Equidyne
Corporation (Equidyne);                                                                                                                                                                                                                                    
|-- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|  
|2. |  | Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by
this quarterly report;
|  
|3. |  | Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all
material respects the financial condition, results of operations and cash
flows of Equidyne as of, and for, the periods presented in this quarterly
report;                         
|  
|4. |  | Equidynes other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures and
internal controls and procedures (as defined in Exchange Act Rules 13a-14
and 15d-14) for Equidyne and have:                                                                                



| | a) |  | designed such disclosure controls and procedures to ensure
that material information relating to Equidyne, including its
consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this
quarterly report is being prepared;
| | -- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| | b) |  | evaluated the effectiveness of Equidynes disclosure controls
and procedures as of a date within 90 days prior to the filing date
of this quarterly report (the Evaluation Date); and                                                                                                  
|
| | c) |  | presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;                                                                                                                  



|5. |  | Equidynes other certifying officer and I have disclosed, based on
our most recent evaluation, to Equidynes auditors and the audit
committee of Equidynes board of directors:
|-- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | a) |  | all significant deficiencies in the design or operation of
internal controls which could adversely affect Equidynes ability to
record, process, summarize and report financial data and have
identified for Equidynes auditors any material weaknesses in
internal controls; and
| | -- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| | b) |  | any fraud, whether or not material, that involves management
or other employees who have a significant role in Equidynes
internal controls; and                                                                                                                                  



|6. |  | Equidynes other certifying officer and I have indicated in this
quarterly report whether or not there were any significant changes in
Equidynes internal controls or in other factors that could significantly
affect internal controls subsequent to the date of our most recent
evaluation, including any corrective actions with regard to significant
deficiencies and material weaknesses.
|-- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Date: June 12, 2003.

| |     |                        
| | --- | -----------------------
| | By: | /s/ Jeffery B. Weinress
| |     |                        
| |     | Jeffery B. Weinress    
| |     | Chief Financial Officer

16



---



##### Table of Contents






EQUIDYNE CORPORATION
INDEX TO EXHIBITS

|            |  |                                                                                                                                                                        
|----------- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Exhibit No. |  | Description                                                                                                                                                            
|            |  |                                                                                                                                                                        
|99.1*       |  | Certification by Marcus R. Rowan, Chief Executive Officer, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.   
|            |  |                                                                                                                                                                        
|99.2*       |  | Certification by Jeffery B Weinress, Chief Financial Officer,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002.

* filed herewith

17